Venturi vacuum better than peristaltic during phaco

Article

When performing phacoemulsification, using a venturi-based vacuum may result in reduced clearance time of lens material compared to a peristaltic-based vacuum, according to new research.

When performing phacoemulsification, using a venturi-based vacuum may result in reduced clearance time of lens material compared to a peristaltic-based vacuum, according to researchers at the John A. Moran Eye Center Laboratories, University of Utah, USA. In addition, the venturi-based vacuum may better mitigate fragment bounces off the tip, or ‘chatter’.

In a study published in the Journal of Cataract and Refractive Surgery, the researchers conducted an experimental study to evaluate the efficiency of peristaltic-based and venturi-based vacuums during phaco.

Using porcine lenses hardened with formalin and cut into 2.0 mm cubes, the researchers used a phacoemulsification machine (WHITESTAR Signature Phacoemulsification System, Abbott Medical Optics) that could switch between peristaltic and venturi-based vacuums to measure time to fragment removal and chatter. They tested both transversal ultrasound and micropulse longitudinal motions, and found the venturi-based vacuum yielded better efficiency and less chatter than the peristaltic-based vacuum, at lower vacuum levels.

To read the abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.